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Background: Skeletal muscle growth and regeneration depend on the activation of
satellite cells, which leads to myocyte proliferation, differentiation and fusion with existing
muscle fibers. Skeletal muscle cell proliferation and differentiation are tightly coordinated
by a continuum of molecular signaling pathways. The striated muscle activator of
Rho signaling (STARS) is an actin binding protein that regulates the transcription of
genes involved in muscle cell growth, structure and function via the stimulation of actin
polymerization and activation of serum-response factor (SRF) signaling. STARSmediates
cell proliferation in smooth and cardiac muscle models; however, whether STARS
overexpression enhances cell proliferation and differentiation has not been investigated
in skeletal muscle cells.
Results: We demonstrate for the first time that STARS overexpression enhances
differentiation but not proliferation in C2C12 mouse skeletal muscle cells. Increased
differentiation was associated with an increase in the gene levels of the myogenic
differentiation markers Ckm, Ckmt2 and Myh4, the differentiation factor Igf2 and the
myogenic regulatory factors (MRFs)Myf5 andMyf6. Exposing C2C12 cells to CCG-1423,
a pharmacological inhibitor of SRF preventing the nuclear translocation of its co-factor
MRTF-A, had no effect on myotube differentiation rate, suggesting that STARS regulates
differentiation via a MRTF-A independent mechanism.
Conclusion: These findings position STARS as an important regulator of skeletal muscle
growth and regeneration.
Keywords: skeletal muscle, proliferation, differentiation, myogenesis, regeneration
INTRODUCTION
Pre- and post- natal skeletal muscle development and regeneration of mature adult skeletal
muscle require the coordinated control of myocyte proliferation and differentiation (Buckingham
et al., 2003; Bentzinger et al., 2012). Each stage of muscle cell development and maturation
is precisely regulated by the basic helix-loop-helix (bHLH) E-box binding protein family of
myogenic regulatory factors (MRFs; Zhang et al., 1995; Kablar et al., 1997; Perry and Rudnick,
2000; Yokoyama and Asahara, 2011). Serum response factor (SRF) is a MADS box protein
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that interacts with MRFs to further enhance myoblast
proliferation and myotube differentiation (Black and Olson,
1998; Pipes et al., 2006b; Yokoyama and Asahara, 2011). SRF
regulates cytoskeletal dynamics, myogenic gene expression and
myocyte proliferation and differentiation via the transcriptional
control of immediate early genes such as Fos, Lif, Junb and Egr1,
as well as via muscle specific genes including actin and myosin
(Chai and Tarnawski, 2002; Pipes et al., 2006b; Miano et al.,
2007). Attenuating SRF activity disrupts myoblast proliferation
and differentiation (Soulez et al., 1996), while SRF knockdown
impairs skeletal muscle development in vivo (Zhang et al., 2001;
Li et al., 2005). Identifying the molecular factors that regulate
SRF activity is therefore essential to comprehend themechanisms
underlying skeletal muscle development and regeneration.
Among the known SRF regulators, striated muscle activator
of Rho signaling (STARS; also known as MS1 and ABRA) is a
muscle specific actin binding protein that associates with the I-
band, Z-disk and M-line of the sarcomere (Arai et al., 2002). In
conjunction with RhoA, STARS increases actin polymerization,
resulting in the nuclear translocation of the SRF transcriptional
co-activator myocardin-related transcription factor-A (MRTF-
A) and enhanced SRF transcriptional activity (Arai et al., 2002;
Kuwahara et al., 2005). STARS is responsive to mechanical
stress and its expression increases in rodent cardiac muscle in
response to pressure overload and in rabbit smooth muscle
following fluid shear-induced arteriogenesis (Mahadeva et al.,
2002; Kuwahara et al., 2007; Troidl et al., 2009). In human skeletal
muscle, we and others have shown that STARS is increased
in response to resistance and endurance acute exercise and
exercise training (Lamon et al., 2009; MacNeil et al., 2010;
Wallace et al., 2011). STARS may therefore act as a sensor to
transduce extracellular mechanical stress signals to activate the
molecular pathways regulating muscle development, growth and
regeneration. STARS is transcriptionally regulated by MEF2,
MyoD, PGC-1α/ERRα and SRF, transcription factors playing
multiple roles in myocyte proliferation and differentiation (Naya
and Olson, 1999; Handschin et al., 2003; Kuwahara et al., 2007;
Ounzain et al., 2008; Murray and Huss, 2011; Wallace et al.,
2011; Chong et al., 2012). In addition, STARS can regulate its
own expression via a feed-forward mechanism that requires SRF
binding to the serum response element (SRE) located on the
STARS promoter (Chong et al., 2012). STARS is expressed during
skeletal muscle early embryonic development and its expression
increases during post-natal muscle development (Arai et al.,
2002; Peng et al., 2008; Chong et al., 2012). In vitro, the Stars
gene is more highly expressed in terminally differentiated skeletal
myotubes than in proliferating myoblasts (Ounzain et al., 2008).
Overexpressing STARS in porcine smooth muscle cells and in
the A10 rat vascular smooth muscle cell line (Troidl et al., 2009)
accelerates proliferation, supporting a role for STARS in muscle
development.
Here we test the hypothesis that STARS may play a similar
role in the regulation of skeletal muscle cell proliferation
and extend our investigations to myotube differentiation. We
report for the first time that STARS overexpression in C2C12
mouse muscle cells enhances cell differentiation, but not
proliferation, and upregulates the expression of several myogenic
differentiation markers, differentiation factors and MRFs. CCG-
1423, a pharmacological inhibitor of SRF that limits the nuclear
translocation of MRTF-A, did not attenuate basal or STARS-
induced increase in differentiation rate, suggesting that STARS
regulates C2C12 cells differentiation via a MRTF-A-independent
pathway.
MATERIALS AND METHODS
Construction of pFLAG-mSTARS
Expression Vector
The cDNA for mouse STARS was subcloned into the pFLAG-
CMV4 (Sigma-Aldrich, Castle Hill, NSW) mammalian
expression plasmid and was designated pFLAG-mSTARS. The
DNA template used to produce the mouse STARS DNA fragment
was the pBluescript-mouseSTARS plasmid, which was previously
cloned by our group. Polymerase chain reaction (PCR) using
specifically designed primers (Geneworks, Hindmarsh, SA) was
performed to amplify the mouse STARS DNA sequence and
incorporate the desired restriction enzyme sites, EcoRI, and
BamHI. PCR products were separated on a 1.0% agarose gel
and the ∼1000 base mouse STARS DNA fragment was extracted
and purified using the QIAquick Gel extraction Kit (QIAGEN,
Doncaster, VIC). The mouse STARS DNA fragment and pFLAG-
CMV4 plasmid were digested using the EcoRI and BamHI
restriction enzymes (NEB, Ipswich, MA) and subsequently
ligated to produce the pFLAG-mSTARS plasmid. Amplification
of pFLAG-mSTARS was achieved by transformation into 5-α
Competent E. coli (High Efficiency) cells (NEB, Ipswich, MA)
and plasmid DNA extraction and purification was performed
using the QIAGEN plasmid kit (QIAGEN, Doncaster, VIC).
Finally, automated sequencing (Applied Genetic Diagnostics,
Parkville, VIC) was performed.
Cell Culture
C2C12 mouse myoblasts (ATCC, Manassas, VA) were
maintained in complete Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS;
Life Technologies, Melbourne, Australia) at 37◦C and 5% CO2.
For differentiation experiments, when cultures approached
confluence (∼90% confluent), medium was changed to
differentiation medium (DMEM) supplemented with 2%
horse serum (HS; Life Technologies, Melbourne, Australia).
Differentiation medium was replaced every 24 h.
Transient Transfection with
pFLAG-mSTARS in C2C12 Myoblasts
C2C12 myoblasts (1.0–2.0 × 104 cells per well) were plated into
six-well plates or 35mm µ-Dishes (ibidi, Munich, Germany)
24 h before transfection. Myoblasts were transiently transfected
with the pFLAG-mSTARS or pFLAG-CMV4 (Sigma-Aldrich,
Castle Hill, NSW) plasmid using Lipofectamine 2000 (Life
Technologies, Mulgrave, VIC). Myoblasts were exposed to
transfection reagents for 24 h, following what myoblasts were
incubated in complete DMEM (10% FBS) for 24 h. RNA and
protein were harvested for RT-PCR gene expression and western
blot analysis, respectively.
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MRTF-A/SRF Transcriptional Inhibition
with CCG-1423 in C2C12 Myoblasts
To provide proof-of concept that the pharmacological inhibitor
CCG-1423 prevents MRTF-A translocation to the nucleus during
all stages of C2C12 cells differentiation, 2.0 × 104 or 2.0 ×
105 myoblasts were plated in 6 well plates or 35mm µ-
Dishes (ibidi, Munich,Germany), respectively. Myoblasts were
allowed to growth for 48 h in growth medium as described
above, following what the medium was replaced by serum-
free DMEM supplemented with either 5µM CCG-1423 (Merck
Millipore, Kilsyth, VIC) or dimethyl sulfoxide (DMSO) at a final
concentration of 0.1%. Similarly, myotubes were differentiated as
described above and were serum-starved after either 48 or 96 h of
differentiation. Following overnight incubation, the medium was
changed to DMEM supplemented with 20% FBS containing the
same concentrations of CCG-1423 or DMSO, respectively. After
1 h, the cells were prepared for immuno-localisation.
BrdU Assay
The rate of C2C12 myoblast proliferation was assessed using
the colorimetric 5-bromo-2′-deoxy-uridine (BrdU) Labeling and
Detection Kit III assay (Roche Applied Science, Indianapolis,
USA) modified as follows. C2C12 cells were plated at a
concentration of 104 cells/ml in a 6-well tissue culture
plate. Twenty-four hours later, myoblasts were transfected
with pFLAG-mSTARS or pFLAG-CMV4 as described above,
following what myoblasts were incubated in complete DMEM
(10% FBS) for 24 h. Twenty-four hours before the analysis, the
BrdU label reagent and CCG-1423 or DMSO treatment were
added to the medium as described above. Nucleases were used
to fragment DNA and BrdU incorporation into the DNA was
detected using a horseradish peroxidase conjugated anti-BrdU
antibody. Following the addition of the peroxidase substrate
ABTS (2,2′-azino-bis, 3-ethylbenzthiazoline-6-sulphonic acid),
fluorescence was detected at 405 nm.
DNA Synthesis Using Deuterated Water
In addition to the BrdU cell proliferation assay, C2C12 myoblast
proliferation was confirmed by measuring DNA synthesis using
deuterated “heavy” water (2H2O). The use of the stable isotopic
tracer 2H2O for measuring DNA synthesis has numerous
advantages over other existing tracer methods including virtually
no cell toxicity (at low 2H2O concentrations, <10%), true
precursor uniformity and greater tracing potential of the
nucleotide synthesis pathways (Busch et al., 2007). C2C12 cells
were prepared as described above for the BrdU assay. Twenty-
four hours before the analysis, the culture medium containing
5% BSA was enriched with 2H2O at a concentration of 4%
and analysis performed as detailed previously (Kloehn et al.,
2015). Briefly, 2000–5000 ng of cell nucleic acid was extracted,
enzymatically hydrolyzed, and dephosphorylated (Busch et al.,
2007) and the released nucleosides were derivatized with
O-(2,3,4,5,6-pentafluorobenzyl) hydroxylamine hydrochloride
(PFBHA HCl, 25mg/ml in water; Sigma-Aldrich, Castle Hill,
NSW) at 90◦C, pH 2 for 3 h. Deoxyribose sugars are released from
nucleobases during oximation and their PFBHA derivative was
extracted in ethyl acetate/hexane (1:1) and dried under nitrogen.
The dried samples were then silylated by addition of ethyl acetate
(20µl) and N,O-bis(trimethylsilyl) trifluoroacetamide reagent
(40µl BSTFA + 1% TMCS) (Thermo Scientific, Rockford, IL)
and incubated at 90◦C for 30min. The perfluorotritrimethylsilyl
derivative of deoxyribose (MW: 545) was analyzed by GC/MS
in positive chemical ionization mode using methane as reagent
gas. The M0-M1 fragment ions [M+1-16]+ of deoxyribose (530–
531m/z), corresponding to the loss of CH4, were analyzed and
the excess M1 molar enrichments (EM1 %) calculated (Busch
et al., 2007; Kloehn et al., 2015).
MRTF-A Cellular Localization
To determine MRTF-A cell localization, myoblasts were
fixed with 4% paraformaldehyde (PFA)/PBS for 10min after
incubation with DMEM supplemented with 20% FBS or serum-
free DMEM for 1 h. Cells were permeabilised in 0.1% Trition
X-100/PBS for 5min and blocked with 1% BSA/PBS for 1 h at
room temperature. Cells were incubated overnight at 4◦C with a
MRTF-A antibody (H-140) (sc-32909; Santa Cruz Biotechnology
Inc, Dallas TX) diluted 1:500 in 1% BSA/PBS and subsequently
with an Alexa Fluor R© 594 goat anti-rabbit IgG secondary
antibody (Life Technologies, Melbourne, VIC) diluted 1:1000
and 0.1µg/ml DAPI stain (Sigma-Aldrich, Castle Hill, NSW)
in 1%BSA/PBS for 1 h at room temperature. Cell images
were obtained using the Olympus Fluoview FV10i confocal
laser scanning microscope with dedicated software at a 150x
magnification for myoblasts and at a 120x magnification for
myotubes using consistent fluorescence thresholds and exposure
times. The ratio between MRTF-A fluorescence in the nuclei
against total MRTF-A fluorescence in the entire cell was
calculated from a minimum of 10 images per group using the
Image J software (U. S. National Institutes of Health, Bethesda).
Adenoviral Infection with ADV-STARS
Adenoviral constructs containing the mouse STARS (ADV-
STARS) or the control gene LacZ (ADV-LacZ) were a generous
gifts from Eric N. Olson, The University of Texas Southwestern
Medical Center. C2C12 myoblasts were plated in six-well tissue
culture plates or 35mm µ-Dishes in complete DMEM (10%FBS)
and allowed to reach ∼90% confluence. Cells were infected with
a multiplicity of infection (MOI) of 100 for both the ADV-
STARS and the ADV-LacZ in differentiation medium (DMEM)
supplemented with 2% HS. Cells were allowed to differentiate for
5 days and medium was replaced every 24 h. RNA and protein
were harvested at day 1, 3, and 5 of the differentiation process for
RT-PCR gene expression and western blot analysis.
Quantification of Myotube Fusion
Following 5 days of differentiation, C2C12 myotubes were fixed
with 4% PFA/PBS for 10min. Fixed cells were permeabilised
in 0.1% Trition X-100/PBS and blocked with 1% BSA/PBS for
1 h at room temperature. Cells were incubated overnight at
4◦C with a primary antibody against sarcomeric myosin (MF-
20, Developmental Studies Hybridoma Bank) diluted 1:50 in
1% BSA/PBS. Following this, the cells were incubated with an
Alexa Fluor R© 488 goat anti-mouse IgG secondary antibody (Life
Technologies, Melbourne, VIC) diluted 1:1000 and 0.1µg/ml
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DAPI stain (Sigma-Aldrich, Castle Hill, NSW) in 1% BSA/PBS
for 1 h at room temperature. Cell images were obtained using
the Olympus Fluoview FV10i confocal laser scanningmicroscope
with dedicated software at a 20x magnification. To assess
myogenic differentiation, the number of DAPI-stained nuclei
within the sarcomeric myosin positive myotubes (multinucleated
cells, i.e., ≥2 nuclei) was determined and expressed as a
percentage of the total number of nuclei analyzed per image.
A minimum of 40 images per group (from two separate
experiments) were analyzed using the ImageJ Software (National
Institutes of Health, Bethesda, MA).
MRTF-A/SRF Transcriptional Inhibition
with CCG-1423 in C2C12 Myotubes
Confluent (∼90%) C2C12 myoblasts were infected with either
the ADV-STARS or the vector control adenovirus (ADV-LacZ)
as described above. The cells were then treated with either
5µM CCG-1423 (Merck Millipore, Kilsyth, VIC) or control
vehicle (DMSO) in DMEM (2%HS) for 24 h. The final DMSO
concentration in both treatments was 0.1%. Cells were allowed to
differentiate for 5 days and treatments were replaced every 24 h.
Cytotoxicity Assay
Cytotoxicity of the SRF inhibitor CCG-1423 was assessed using
the CellToxTM Green Cytotoxicity Assay (Promega, Auburn,
VIC) according to the manufacturer’s instructions. Briefly,
C2C12 myoblasts were seeded at a density of 0.5 × 104 cells
per well in back-walled 96-well tissue culture plates (ibidi,
Munich, Germany) and grown in growth media for 48 h.
Myoblasts were then treated with 5µM CCG-1423 (Merck
Millipore, Kilsyth, VIC) or 0.1% DMSO in serum free media for
24 h. C2C12 myotubes were differentiated as described above.
After 96 h of differentiation, the cells were treated with 5µM
CCG-1423 (Merck Millipore, Kilsyth, VIC) or 0.1% DMSO in
serum free media for 24 h and fluorescence was measured at
485–500 nmEX/520–530 nmEM using a Synergy 2 multi-mode
microplate reader (Biotek, Currumbin, QLD) to assess cell
viability.
RNA Extraction
Total RNA was extracted using the Tri-Reagent R© Solution
(Ambion Inc, Austin TX) according to the manufacturer’s
protocol. First-strand cDNA was generated from 1 to 2µg
RNA in 20µL reaction buffer using the High Capacity RNA-
to-cDNA kit (Applied Biosystems, Forster City, CA) according
to the manufacturer’s protocol. Before diluting cDNA, 1µL
ribonuclease H (Rnase H; Life Technolgies, Mulgrave, VIC)
was added to each sample and incubated at 37◦C for 30min.
Following this, cDNA was diluted in NFW to 5 ng/µL and stored
at−20◦C until further analysis.
Real Time Quantitative PCR
Real-time PCR was carried out using the Stratagene MX3000
PCR system (Agilent Technologies, Santa Clara CA) to measure
the mRNA levels of genes of interest. To compensate for
variations in input RNA amounts and efficiency of the reverse
transcription, data was normalized to single-stranded DNA
(ssDNA) content that was determined using the Quanti-iT
OliGreen ssDNA Assay Kit (Molecular Probes, Eugene, OR).
RT-PCR primer details for the mouse genes are provided in
Table 1.
Protein Extraction
Total protein was extracted using 1x RIPA buffer (Millipore,
North Ryde, NSW) with 1µL/mL protease inhibitor cocktail
(Sigma-Aldrich, Castle Hill, NSW) and 10µL/mL Halt
Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific,
Rockford, IL). Total protein content was determined using the
BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL)
according to the manufacturer’s instructions.
Western Blotting
Electrophoresis and protein transfer were performed using the
XCell Surelock Novex Mini- Cell (Invitrogen, Carlsbad, CA)
system. Protein lysates were separated by SDS-PAGE using
pre-cast NuPAGE R© Novex 4–12% Bis-Tris gels (Invitrogen,
Carlsbad, CA) and transferred to a PVDF membrane (Millipore,
TABLE 1 | Details of mouse primers used for RT-PCR analysis.
Gene GenBank accession number Forward Primer (5′–3′) Reverse primer (5′–3′)
Ckm NM_007710.2 GCGCCGTGTTCGACATC GACTGGCCCTTTTCCAGCTT
Ckmt2 NM_198415.2 ACGCACTGGCCGAAGCATCC GCCAGATCGCCCTTCAGGCC
Egr1 NM_007913.5 GAGCGAACAACCCTATGAGC AGGCCACTGACTAGGCTGAA
Fos NM_010234.2 CACTCCAAGCGGAGACAGAT TGGGCTGCCAAAATAAACTC
Igf1 NM_010512.4 GCTCTGCTTGCTCACCTTCAC CCTCCGTCCACACACGAACT
Igf2 NC_000073.6 CGCTTCAGTTTGTCTGTTCG GGAAGTACGGCCTGAGAGGTA
JunB NM_008416.3 TTGCGGACGGTTTTGTCA CGTCACGTGGTTCATCTTGTG
Lif NM_008501.2 GGCAACCTCATGAACCAGAT ACCATCCGATACAGCTCCAC
Myh4 NM_010855.2 ACAGACTAAAGTGAAAGCC CTCTCAACAGAAAGATGGAT
Myf5 NM_008656.5 CACCACAACCAACCCTAACCA ACTCTCAATGTAGCGGATTGC
Myf6 NC_000076.6 GGTACCCTATCCCCTTGCCA GGGAGTTTGCGTTCCTCTGA
Srf NM_020493.2 ACGACCTTCAGCAAGAGGAA AAGCCAGTGGCACTCATTCT
Stars NM_175456.4 TCAAACGCCCCTTGCTCTC CGTGTTCATCGGCCCACT
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Billerica, MA). Membranes were then incubated at room
temperature for 1 h in blocking buffer supplemented with
5% BSA/PBS. After blocking, membranes were incubated
overnight at 4◦C with the following primary antibodies
diluted 1:1000 in 5% BSA/PBS: STARS (Institute of Medical
and Veterinary Science, Adelaide SA); Myosin, Sarcomeric
(MF-20, Developmental Studies Hybridoma Bank, Iowa City
IA); SRF (Santa Cruz Biotechnology, Dallas, TX (sc-335)).
Following washing the membranes were incubated for 1 h
with the corresponding infrared dye-conjugated secondary
antibodies (Thermo Fisher Scientific, Inc, Rockford, IL). After
washing, the specific proteins were revealed using the Odyssey
Imaging System (LI-COR, Lincoln, NE, USA). GAPDH (G8795,
Sigma-Aldrich, Castle Hill, NSW) was used to control for
protein loading and individual protein band optical densities
were determined using the Odyssey Infrared Imaging System
software.
Statistical Analyses
All data are reported as mean ± SEM. To ensure homogeneity
of variance, all data was log10-transformed and analyses
were conducted on these transformed scales. Overexpression
experiments in proliferating C2C12 myoblasts were analyzed
using either a two-tailed unpaired t-test or a one-way analysis of
variance (ANOVA). For every other analysis, amixed-model two-
way ANOVA or a general ANOVA were used to compare group
means using GenStat v16. Diagnostic plots of residuals and fitted
values were checked to ensure homogeneity of variance (a key
assumption for ANOVA). The least significant difference (LSD)
test was used to compare pairs of means. The significance levels
for both the F-tests in the ANOVA and the LSD tests were set
at p < 0.05. Note that the statistical significance reported in
the figures is based on analysis of the transformed data but the
reported means ± S.E.M. are on the original (untransformed)
scale.
RESULTS
Endogenous Expression of STARS During
Proliferation and Differentiation of C2C12
Myocytes
Stars mRNA expression increased by 1.5-fold in confluent
myoblasts when compared to sub-confluent myoblasts
(p < 0.001; Figure 1A); however, there was no significant
increase in STARS protein expression during myoblast
proliferation (Figure 1B). Supplementary Figure 1 displays
the full western blot images of all immunoblot pictures presented
in this manuscript. Stars mRNA levels gradually increased
FIGURE 1 | STARS mRNA and protein expression levels were respectively measured by real-time qPCR and Western blot during C2C12 cells
proliferation and differentiation. STARS mRNA (A) but not protein (B) levels increase in confluent myoblasts (D0; prior to adding differentiation media) when
compared to sub confluent myoblasts (MB). *** different from MB, p < 0.001. STARS mRNA (C) and protein (D) levels increase during myotube differentiation. **
different from D0, p < 0.01, *** different from D0, p < 0.001, ##different from precedent day, p < 0.01.
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during myotube differentiation to reach a 80-fold increase by
differentiation day 5 when compared to proliferating myoblasts
(Figure 1C). When compared to D0, STARS protein levels
concomitantly increased by 2- to 3-fold between differentiation
days 2 and 5 (Figure 1D).
The Effect of STARS Overexpression on
SRF-Target Genes and C2C12 Myoblast
Proliferation
The overexpression of STARS in proliferating C2C12 myoblasts
using a pFLAG-mSTARS plasmid (STARS) resulted in a
substantial increase in Stars mRNA levels (p < 0.001) paralleled
by a 15-fold increase in STARS protein levels (p < 0.001) when
compared to C2C12 myoblasts transfected with a pFLAG-CMV4
plasmid (control) (Supplementary Figures 2A,B).
Immediate early genes function as early regulators of
cell growth. In C2C12 myoblasts overexpressing STARS, the
expression levels of the known SRF-regulated immediate early
genes Egr1 and Junb increased when compared to control
myoblasts (Figures 2A,B; compare white bars only). There was
no effect of STARS on other early genes including Fos, Igf1 and
Lif (data not shown). Analysis of both BrDU and deuterium
incorporation assay did not reveal any difference in myoblast
DNA synthesis with STARS overexpression. Thus, proliferation
rates with STARS overexpression were unaltered (Figure 3 and
Supplementary Figure 2C).
The Effect of SRF Inhibitor CCG-1423 in
C2C12 Myoblasts Overexpressing STARS
Pharmacological SRF inhibitor CCG-1423 blocks the nuclear
translocation of MRTF-A and therefore partially inhibits SRF
activation. We aimed to determine if MRTF-A translocation
was required for the STARS-induced increase in SRF target
FIGURE 3 | STARS overexpression has no effect on C2C12 myoblast
proliferation. Absorbance measured at 405 nm following BrDU incorporation
assay.
FIGURE 2 | Effect of STARS overexpression and inhibition of MRTF-A translocation on known SRF target genes (A,B), STARS mRNA (C) and protein
(D), and SRF mRNA (E) and protein (F). mRNA and protein expression levels were respectively measured by real-time qPCR and Western blot. Inhibition of
MRTF-A translocation by CCG-1423 treatment decreases the mRNA levels of Egr-1 (A), Junb (B), Stars (C), Srf gene (E) and SRF protein levels (F). It has no effect
on STARS protein levels (D). In (A) and (B), post-hoc tests revealed significant differences when comparing the Control DMSO to the STARS DMSO group (* different
from Control DMSO, p < 0.05). DMSO, dimethyl sulfoxide vehicle control; CCG-1423, SRF inhibitor.
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gene expression and if STARS overexpression was able to
counteract the potential negative effect of the inhibitor. CCG-
1423 treatment had no cytotoxic effect on C2C12 myoblasts
when compared to DMSO treatment or to untreated myoblasts
(Supplementary Figure 2D). In C2C12 myoblasts, MRTF-A is
localized within the cytoplasm and the nucleus under serum-
free and serum stimulated (20% FBS) conditions. Following
CCG-1423 treatment, we observed a decrease in MRTF-A
presence in the nucleus in both conditions (p < 0.0001),
providing proof-of-concept that CCG-1423 efficiently attenuates
MRTF-A nuclear translocation in myoblasts (Figures 4A,B).
The expression levels of the SRF immediate early genes Egr1
and Junb were reduced following CCG-1423 treatment (main
effect for treatment, p < 0.01 and p = 0.06, respectively);
however, this decrease could not be prevented by STARS
overexpression (Figures 2A,B). CCG-1423 treatment reduced
endogenous Stars mRNA expression in control myoblasts (0.4-
fold; p < 0.01) and attenuated the increase in exogenous Stars in
myoblasts transfected with the pFLAG-mSTARS plasmid (0.65-
fold; p < 0.01; Figure 2C). These observations were paralleled
by a significant decrease (p < 0.01) in exogenous but not in
endogenous STARS protein expression levels (Figure 2D). SRF
is known to regulate its own transcription. While Srf mRNA
and SRF protein expression levels were not influenced by STARS
overexpression, they were both significantly decreased following
CCG-1423 treatment (p < 0.01; Figures 2E,F).
The Effect of STARS Overexpression on
C2C12 Myotube Differentiation
STARS overexpression in C2C12 myotubes resulted in a gradual
increase in STARS mRNA and protein levels at differentiation
days 3 and 5 (p < 0.05) when compared to control cells
(Figures 5A,B). An increase in differentiation rate following
STARS overexpression was assessed both visually (Figure 5C)
and by the calculation of the myotube fusion index that was
higher in myotubes overexpressing STARS than in control
myotubes (p < 0.001; Figure 5D). In line with this result, STARS
overexpression during differentiation increased the mRNA levels
of the differentiation markers Ckmt2, Ckm and Myh4 (Mhc-
IIb), of the differentiation factor Igf2 and of the MRFs Myf5 and
Myf6 (all p < 0.001) (Figures 7A–E), but not of MyoG mRNA
or protein levels (data not shown) when compared to control
myotubes.
The Effect of SRF Inhibitor CCG-1423 in
C2C12 Myotubes Overexpressing STARS
CCG-1423 treatment demonstrated no cytotoxic effect on C2C12
myotubes when compared to DMSO treatment or to untreated
myotubes (Supplementary Figure 2E). Serum stimulation (20%
FBS) increased nuclear MRTF-A levels in C2C12 myotubes at
differentiation day 3 (p < 0.05) (Figures 6A,B) but not at
differentiation day 5 (Supplementary Figures 2H,G). At day 3,
this increase was attenuated when the cells were treated with
CCG-1423 (p < 0.0001), although MRTF-A presence in the
nucleus also decreased to a smaller extend under serum-free
conditions (Figure 6B). CCG-1423 treatment did not influence
myotube differentiation rate in both control myotubes and
myotubes overexpressing STARS (Figure 5D). CCG-1423 had
no effect on Ckmt2, Ckm, Myf5, Myf6, Igf2 (Figures 7A–E) and
Myog, Stars or Srf expression during differentiation (data not
shown). On the other hand, post-hoc analyses revealed that in
addition to a main treatment effect, CCG-1423 decreased Myh4
gene expression and MHC protein levels at Day 3 and Day 5 in
both groups (Figures 7F,G).
FIGURE 4 | MRTF-A cellular localization following CCG-1234 treatment in serum-stimulated (20% FBS) and serum-free (SF) C2C12 myoblasts.
Immunolocalization of MRTF-A (A). Blue, DAPI staining; Red, MRTF-A; DMSO, dimethyl sulfoxide vehicle control; CCG-1423, SRF inhibitor. In the FBS treated group,
arrows point toward the nuclei where MRTF-A presence is high (DMSO) or attenuated by CCG-1423 treatment (CCG-1423). MRTF-A intensity in the nucleus divided
by total MRTF-A intensity (B). CCG-1423 treatment prevented MRTF-A nuclear translocation in both serum-stimulated (FBS) and serum-free (SF) C2C12 myoblasts.
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FIGURE 5 | STARS mRNA and protein levels gradually increase following overexpression in C2C12 myotubes and STARS overexpression accelerates
myotube differentiation. mRNA and protein expression levels were respectively measured by real-time qPCR and Western blot. STARS mRNA (A) and protein (B)
levels increase during 5 days of myotube differentiation. *** Main effect of STARS overexpression, p < 0.001. * Significantly different from LacZ at the same time point,
p < 0.05. Immunofluorescent staining of MHC (green) and nuclei (blue) in differentiated myotubes at day 5 (C). Myotube fusion index at differentiation day 5 increases
with STARS overexpression but is not influenced by CCG-1423 treatment (D). *** Main effect of STARS overexpression, p < 0.001.
FIGURE 6 | MRTF-A cellular localization following CCG-1234 treatment in serum-stimulated (20% FBS) and serum-free (SF) C2C12 myotubes at
differentiation day 3. Immunolocalization of MRTF-A (A). Blue, DAPI staining; Red, MRTF-A; DMSO, dimethyl sulfoxide vehicle control; CCG-1423, SRF inhibitor. In
the FBS treated group, arrows point toward the nuclei where MRTF-A presence is high (DMSO) or attenuated by CCG-1423 treatment (CCG-1423). MRTF-A intensity
in the nucleus divided by total MRTF-A intensity (B). Serum stimulation (FBS) increased MRTF-A presence in the nucleus when compared to serum-free (SF)
conditions. CCG-1423 treatment prevented MRTF-A nuclear translocation in both serum-stimulated and serum-free C2C12 myotubes.
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FIGURE 7 | The effect of STARS overexpression and inhibition of MRTF-A translocation on C2C12 myotube differentiation markers. mRNA and protein
expression levels were respectively measured by real-time qPCR and Western blot. STARS overexpression increases the mRNA levels of Ckmt2 (A), Ckm (B), Myf6
(C), Igf2 (D), Myf5 (E) and Myh4 (Mhc-IIb) (F) when compared to control myotubes (main effect of STARS, all p < 0.001). In addition, there was a main effect of
CCG-1423 treatment on the expression levels of Myh4 (Mhc-IIb) mRNA (F) and MHC protein (G) (main effect of CCG-1423 treatement, both p < 0.01). In (F) and (G),
post-hoc tests revealed that CCG-1423 treated group was different from DMSO treated group at Day 3 and Day 5 (* different from the DMSO group at the same time
point, p < 0.05).
DISCUSSION
Skeletal muscle growth and regeneration is controlled by
intracellular signals regulating myoblast proliferation and
differentiation into mature multinucleated myotubes (Chambers
and McDermott, 1996). The present study investigated
whether STARS overexpression enhances the proliferation
and differentiation of C2C12 muscle cells. We demonstrate for
the first time that overexpressing STARS at the onset of myoblast
differentiation enhances skeletal muscle cell differentiation. The
increase in myotube fusion index was paralleled by increases in
the mRNA levels of the differentiation markers Ckm, Ckmt2,
Myh4 (Mhc-IIb), of the differentiation factor Igf2 and of the
MRFs Myf5 and Myf6 (MRF4). On the other hand, STARS
overexpression had no effect on myoblast proliferation, although
it increased the mRNA levels of the SRF immediate early genes
Egr1 and Junb. While the pharmacological inhibitor of MRTF-A
translocation CCG-1423 had a negative effect on SRF target gene
expression, myotube differentiation rate was not attenuated.
The expression pattern of the STARS gene and protein during
skeletal muscle cell proliferation and differentiation has only
been partially investigated. In vivo, Stars starts to be expressed
during the early embryonic development of skeletal muscle and
continues to increase during post-natal muscle development
(Peng et al., 2008). We observed an increase in Stars gene
expression during myoblast proliferation and a further gradual
increase during myotube differentiation, confirming previous
observations made in C2C12 cells (Ounzain et al., 2008). For the
first time we extended these observations to the expression levels
of the STARS protein, which significantly increased between
differentiation day 2 and 5. Together with our previous findings
that STARS is required for myotube survival (Wallace and
Russell, 2013), these observations suggest that increasing levels
of STARS are necessary for optimal myocyte development.
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STARS activates SRF-dependant transcription by directly
stimulating the promoters of genes regulated by SRF, such
as Tagln2 (formerly Sm22-α) and Acta1 (formerly α-actin)
(Arai et al., 2002). In skeletal muscle, SRF regulates cell
growth via the transcription of immediate early genes such
as Fos, Lif, Junb and Egr1 (Chai and Tarnawski, 2002; Pipes
et al., 2006a; Miano et al., 2007); genes that enhance myoblast
proliferation in L6 and C2C12 cells (Rahm and Sejersen,
1990; Chalaux et al., 1998). In rat H9c2 cells, overexpressing
STARS significantly increased the expression levels of several
SRF target genes, including Junb, Lif and IL6 (Koekemoer
et al., 2009; Chong et al., 2012). Here we report that STARS
overexpression in skeletal muscle myoblasts increased the mRNA
levels of some, but not all immediate early genes. STARS is
however not the only signaling pathway able to activate SRF
transcriptional activity. The MAPK pathway typically regulates
the expression of SRF immediate early genes (Posern and
Treisman, 2006; Sun et al., 2006; Muehlich et al., 2008) and
STARS and MAPK signaling are believed to play exclusive
but complementary roles in SRF transcriptional activation
(Janknecht et al., 1993; Hill et al., 1995; Sotiropoulos et al.,
1999; Gineitis and Treisman, 2001; Copeland and Treisman,
2002; Murai and Treisman, 2002). Our results support the
observation (Selvaraj and Prywes, 2004) that the STARS pathway
also influences SRF control of a subset of immediate early
target genes, including Egr1 and Junb. Despite the positive
regulation of the early regulators of gene growth Egr1 and Junb,
STARS overexpression did not induce an increase in skeletal
muscle cell proliferation. While STARS increases proliferation
in porcine smooth muscle cells and in the A10 rat vascular
smooth muscle cell line (Troidl et al., 2009), it has no
effect on the proliferation of porcine aortic endothelial cells
(Troidl et al., 2009) or of the H9c2 rat cardiac cell line
(Koekemoer et al., 2009), suggesting cell- and species-specific
influences.
We then investigated whether the STARS-induced increase
in several SRF target genes was a direct consequence of STARS
facilitating the nuclear translocation of the SRF transcriptional
co-activator MRTF-A. The pharmacological SRF inhibitor CCG-
1423 inhibits MRTF-A co-activation of SRF transcriptional
activity by preventing MRTF-A nuclear translocation. In H9c2
rat muscle cells, chromatin immunoprecipitation showed that
CCG-1423 completely blocked STARS proximal reporter activity
(Chong et al., 2012). In the present study, CCG-1423 treatment
resulted in a significant decrease in the mRNA expression
levels of the SRF target genes Egr1 and Junb. This effect was
independent of STARS expression levels, suggesting that supra-
physiological levels of STARS in myoblasts are not sufficient to
counteract the negative effect of CCG-1423. The effect of STARS
on known SRF target gene expression may therefore not be
via their direct regulation by STARS, but via STARS upstream
regulation of the MRTF-A/SRF axis, supporting observations
made in NIH 3T3 cells (Kuwahara et al., 2005). Of interest,
one study showed that MRTF-A expression in pulmonary
fibromyoblasts was SRF-dependant and was inhibited by CCG-
1423 treatment (Sandbo et al., 2011); findings that were not
observed in C2C12 myoblasts in the present study. Finally,
CCG-1423 treatment reduced Stars and Srf mRNA levels and
SRF protein levels, supporting the idea that (1) SRF can positively
regulate its own transcription (Miano et al., 2007) and (2) STARS
can also regulate its own transcription, which may require SRF
binding to the SRE located on the STARS promoter; a binding
that is completely prevented by the use of the CCG-1423 inhibitor
(Chong et al., 2012).
Overexpressing STARS at the onset of myoblast differentiation
enhanced myogenic differentiation in skeletal muscle cells as
indicated by an increased fusion index and elevated levels of
several known makers of myotube differentiation including
creatine kinase and myosin heavy chain (Chamberlain et al.,
1985; Brown et al., 2012) as well as the differentiation
factor Igf2 (Florini et al., 1991; Magri et al., 1991) and
the MRFs Myf5 and Myf6 but not MyoG. We showed that
CCG-1423 prevented MRTF-A translocation to the nucleus in
differentiating myotubes; however CCG-1423 treatment did not
influence myotube differentiation in control cells or in STARS
overexpressing cells. Nevertheless, it had a limited effect on
some of the differentiation markers and caused a reduction
in the expression levels of the Ckm gene and MHC protein
at differentiation day 3 and day 5 in both control myotubes
and myotubes overexpressing STARS. The Ckm gene is a
SRF target gene possessing a CArG box that functions as a
SRF-binding site in its cis-regulatory region (Vincent et al.,
1993). Reduced SRF transcriptional activity negatively regulates
the muscle creatine kinase (Ckm) gene and mouse muscle
lacking SRF display very low levels of Ckm (Charvet et al.,
2006). As CCG-1423 did not prevent MRTF-A translocation in
myotubes at differentiation day 5, it is likely that the observed
effects on myosin heavy chain gene and protein expression
levels were carried on from an earlier time point. Altogether,
these results support the hypothesis that skeletal muscle cell
differentiation is marginally under the control of the MRTF-
A/SRF transcriptional pathway and suggest the existence of a
mechanism that functions in parallel and/or complementary to
MRTF-A.
It is known that STARS influences SRF-mediated gene
transcription via a mechanism involving RhoA signaling (Arai
et al., 2002); a pathway that is essential for the differentiation
of smooth, cardiac and skeletal muscle cells (Aoki et al.,
1998; Du et al., 2004). The precise mechanism underlying
the STARS–RhoA interaction is unknown. However, in non-
muscle cells, STARS and RhoA can act independent of each
other and individually enhance SRF transcriptional activity
(Arai et al., 2002), although their combined overexpression
augments this effect. Our results indicate that STARS plays an
essential role in the differentiation from myoblasts to mature
myotubes; to which extent this process is mediated by RhoA is
unknown. Another hypothesis relies on observations reporting
that Z disc proteins, such as calsarcin-1, can negatively regulate
calcineurin/NFAT (nuclear factor of activated T cells) signaling
in cardiac tissue (Frey et al., 2004; Gautel, 2008). Calcineurin
plays an important regulatory role in skeletal muscle remodeling
(Ryder et al., 2005) via the activation of transduction pathways
involving calcium–calmodulin-dependent protein kinase IV
(CaMKIV; Wu et al., 2002), MEF-2 and PGC-1α (Lin et al.,
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2002). STARS may activate a calcium-dependent regulatory
pathway that assists with cell differentiation, however this has
not been experimentally validated. In both cases, the lack
of effect of CCG-1423 treatment on myotube fusion index
suggests that MRTF-A would not be an obligatory part of these
mechanisms.
CONCLUSION
In conclusion, we show for the first time that STARS
overexpression enhances the differentiation process in mouse
C2C12 muscle cells. Overexpression of STARS in proliferating
C2C12 myoblasts was associated with increased expression
of SRF target genes involved in muscle cell growth but did
not lead to increased proliferation. STARS overexpression
in differentiating myotubes was associated with increased
expression of typical and muscle-specific differentiation genes
associated with cell structure and metabolism. STARS-induced
increase in myotube differentiation was not influenced by CCG-
1423 treatment, suggesting that STARS-mediated control of
differentiation may also be via an MRTF-A/SRF independent
mechanism. Overall, these in vitro findings position STARS
as an important potential regulator of skeletal muscle growth
and regeneration and this now requires experimental in vivo
validation in an appropriate mouse model.
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overexpression in C2C12 myoblasts. (B) STARS protein levels following STARS
overexpression in C2C12 myoblasts. (C) 2H Enrichment expressed as a
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measured at 485 nm following a cytotoxicity assay in C2C12 myoblasts. (E)
Absorbance measured at 485 nm following a cytotoxicity assay in C2C12
myotubes. (H) MRTF-A cellular localization following CCG-1234 treatment in
serum-stimulated (20% FBS) and serum-free (SF) C2C12 myotubes at
differentiation day 5. Immunolocalization of MRTF-A. Blue, DAPI staining; Red,
MRTF-A; DMSO, dimethyl sulfoxide vehicle control; CCG-1423, SRF inhibitor. (G)
MRTF-A intensity in the nucleus divided by total MRTF-A intensity in C2C12
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